GUJARAT KIDNEY & SUPER SPECIALITY IPO
At a Glance: Gujarat Kidney & Super Speciality IPO
| IPO Period | 22nd – 24th Dec 2025 |
|---|---|
| Listing on | 30 Dec 2025 |
| Price Band | ₹108 – ₹114 per equity share |
| Lot Size & Minimum Investment | 128 shares – ₹14,592 |
| Total Issue Size | ₹250.80 Crores |
Key Dates for Your Calendar
- Opening Date: 22 Dec 2025
- Closing Date: 24 Dec 2025
- UPI Payment Deadline: 24 Dec 2025 (5 PM)
- Allotment Announcement: 26 Dec 2025
- Refund Processing: 29 Dec 2025
- Demat Credit: 29 Dec 2025
- Stock Market Listing: 30 Dec 2025
- Mandate Validity End: 09 Jan 2026
- Anchor Investor Lock-in Release (50%): 25 Jan 2026
- Anchor Investor Lock-in Release (Remaining): 26 Mar 2026
*Dates may be revised as per official updates.
Exploring Gujarat Kidney & Super Speciality Limited
Founded in 2019, Gujarat Kidney & Super Speciality Limited has rapidly grown into a prominent regional healthcare provider. The company operates a robust network of mid-sized multispeciality hospitals strategically located across central Gujarat. Initially established with a focused vision, the organization later expanded its clinical scope and rebranded to reflect its comprehensive range of services, emphasizing its leadership in kidney and super-speciality care.
The company’s core mission revolves around delivering integrated secondary and tertiary care. Its services are comprehensive, encompassing inpatient and outpatient care, advanced diagnostics, a wide array of surgical procedures, critical care management, and convenient in-house pharmacy operations within its hospital premises. This integrated approach ensures a seamless patient experience and holistic treatment.
Promoted by a team of experienced medical and managerial professionals, including Dr. Pragnesh Yashwantsinh Bharpoda, Dr. Bhartiben Pragnesh Bharpoda, Dr. Yashwantsinh Motisinh Bharpoda, and Anitaben Yashwantsinh Bharpoda, the company benefits from strong foundational expertise. Today, Gujarat Kidney & Super Speciality Limited successfully manages seven hospitals and four in-house pharmacies. These facilities are spread across key cities and towns such in Vadodara, Godhra, Bharuch, Borsad, and Anand, establishing a significant footprint in the region.
The company boasts a substantial total capacity of 490 beds, with 445 approved beds and 340 operational beds, demonstrating its readiness to serve a large patient base. Its business model effectively combines owned and strategically acquired facilities, providing a scalable framework for expansion and efficient integration of new units. Through continuous technology adoption and a focus on specialty-driven services, Gujarat Kidney & Super Speciality Limited is well-positioned to address the increasing healthcare demands in both semi-urban and urban markets of Gujarat, making it a pivotal player in the region’s healthcare landscape.
IPO Structure and Capital Generation
| Total Funds Raised | ₹250.80 Crores |
|---|---|
| Fresh Issue Component | ₹250.80 Crores |
| Offer for Sale Component | ₹0 Crores |
The Gujarat Kidney & Super Speciality IPO is entirely a fresh issue, aiming to raise ₹250.80 Crores. This indicates that all proceeds from the offering will directly flow into the company, bolstering its balance sheet and supporting its ambitious growth and expansion plans. This structure reflects a commitment to enhancing operational capabilities and strategic investments rather than facilitating promoter dilution, which can be a positive signal for potential investors looking for companies focused on internal capital deployment for future development.
Strategic Deployment of IPO Proceeds
| Objective | Amount (INR Crores) | Allocation % |
|---|---|---|
| Strategic Acquisitions & Stake Enhancements | 100.18 | 39.94% |
| Capital Expenditure for Expansion & Technology | 36.93 | 14.72% |
| Repayment/Prepayment of Secured Borrowings | 1.20 | 0.48% |
| General Corporate Purposes | 112.49 | 44.86% |
The capital raised through the Gujarat Kidney & Super Speciality IPO is earmarked for several strategic initiatives designed to fuel the company’s growth and solidify its market position. A significant portion, amounting to ₹100.18 Crores (39.94%), is allocated towards strategic acquisitions, including the purchase of Parekhs Hospital in Ahmedabad, part-payment for Ashwini Medical Centre, and acquiring additional stake in Harmony Medicare in Bharuch. These acquisitions are crucial for expanding the company’s geographic reach and service offerings.
Furthermore, ₹36.93 Crores (14.72%) will be invested in capital expenditure. This includes funding for a new hospital in Vadodara and the acquisition of advanced robotics equipment for the existing Vadodara facility, showcasing the company’s commitment to technological advancement and infrastructure development. A minor portion of ₹1.20 Crores (0.48%) is designated for the repayment or prepayment of secured borrowings, which will help in optimizing the company’s capital structure. The remaining ₹112.49 Crores (44.86%) is allocated for general corporate purposes, providing the company with financial flexibility for various operational needs, strategic investments, and working capital requirements as it continues its expansion trajectory.
Core Strengths and Strategic Advantages
- Specialized Expertise in Renal Sciences: Gujarat Kidney & Super Speciality Limited possesses robust capabilities in renal sciences, complemented by well-established urology subspecialties. This focused expertise allows the company to cater to a critical and growing segment of healthcare needs, distinguishing it as a leader in specialized medical care within its operating regions.
- Optimally Located Hospitals: The company’s hospitals are strategically located and sized appropriately to maximize efficiency and generate strong capital returns. This thoughtful placement ensures accessibility for patients while also contributing to the optimal utilization of resources and operational profitability, supporting sustained growth.
- Skilled Professional Workforce: Gujarat Kidney & Super Speciality Limited has a proven track record in attracting, effectively training, and retaining a highly skilled team of medical professionals. This dedicated workforce is fundamental to maintaining high standards of patient care and fostering clinical excellence across its network.
- Commitment to Infrastructure and Affordable Care: The company consistently invests in upgrading its infrastructure and refining clinical processes. These continuous enhancements are designed to support the delivery of high-quality, yet affordable, healthcare services, making advanced medical treatment accessible to a broader population.
- Solid Operational and Financial Performance: With a demonstrated history of strong operational management and robust financial performance, the company has established a credible track record of growth. This consistent performance underscores its resilience and effective business strategies in a competitive healthcare environment.
Considerations and Potential Challenges
- Acquisitions from Promoters and Related-Party Risks: The company has a history of acquiring hospitals from its promoters and may continue this practice. While such acquisitions can facilitate growth, they also introduce potential related-party transaction risks, which require careful scrutiny to ensure fair valuation and alignment of interests with all shareholders.
- Integration and Expansion Risks: Growth through acquisitions and rapid expansion across multiple hospital units inherently carries operational, financial, and regulatory risks. Successfully integrating new facilities, managing diverse operational models, and complying with varied regulatory frameworks can add significant complexity to management and operations.
- Increased Management Complexity with Expansion: The rapid pace of expanding its hospital network across multiple locations can lead to increased management and operational complexity. Ensuring consistent service quality, maintaining efficient resource allocation, and supervising a larger, more dispersed workforce present ongoing challenges for the management team.
- Dependence on Promoter Expertise: The company’s strategic direction and operational success are significantly reliant on the expertise and leadership of its promoters. This concentration of expertise could pose continuity risks if key promoter-led talents were to become unavailable, potentially impacting decision-making and strategic execution.
- Service Breadth Limitations in Some Hospitals: Certain hospitals within the company’s network may lack specific departments, which could limit the overall breadth of services offered. While specialization can be a strength, the absence of certain key departments might affect patient retention for comprehensive care needs, potentially impacting revenue diversity.
Live Subscription Trends
Subscription statistics based on the latest available information:
| Investor Category | Shares Reserved (Lakhs) | Shares Applied (Lakhs) | Subscription (Times) |
|---|---|---|---|
| Qualified Institutional Buyers (QIB) | – | – | – |
| Non-Institutional Investors (NII) | – | – | – |
| Retail Individual Investors (RII) | – | – | – |
| Total | – | – | – |
*Subscription data will be updated post-IPO opening and is subject to official disclosures.
Participating in the IPO: Your Next Steps
Investors keen on participating in the Gujarat Kidney & Super Speciality IPO can apply through the official Dhan Kirti IPO platform. Ensure your application is submitted before the subscription window officially closes to be considered for allotment.
